A phase 3 trial for donanemab, Eli Lilly’s Alzheimer’s drug candidate, showed significant progress in slowing down cognitive and functional decline in people who are in early stages of the disease’s progression, according to a July 17 news release.
Read the full post on Becker's Hospital Review - Healthcare News
